Epalrestat

Drug profile

Key facts

Epalrestat is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1992. DrugCentral lists 10 molecular targets, including Akr1b1, GSK3B and AKR1B1. Recorded indications include Diabetic neuropathy.

• Molecular targets: Akr1b1, GSK3B, AKR1B1 and AKR1B1 (10 listed in DrugCentral).
• Indications: Diabetic neuropathy.
• Molecular formula: C15H13NO3S2; molecular weight 319.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetic neuropathy

Mechanism & targets

Molecular targets (10)

Target	Gene	Action	Activity
Aldose reductase	Akr1b1	unknown	IC50 8.00
Glycogen synthase kinase-3 beta	GSK3B	unknown	IC50 7.68
Aldose reductase	AKR1B1	inhibitor	IC50 7.68
Aldose reductase	AKR1B1	unknown	IC50 6.77
Aldo-keto reductase family 1 member B10	AKR1B10	unknown	IC50 6.48
Alcohol dehydrogenase [NADP(+)]	AKR1A1	unknown	IC50 5.82
Alcohol dehydrogenase [NADP(+)]	Akr1a1	unknown	IC50 5.82
Cytochrome P450 4A11	CYP4A11	inhibitor	IC50 5.74
Alcohol dehydrogenase [NADP(+)]	AKR1A1	unknown	IC50 5.59
Sorbitol dehydrogenase	SORD	unknown	IC50 4.17

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1992-01-01	YEAR INTRODUCED	—	—

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cerebral infarction	56.7

Chemical structure

• Molecular formula: C₁₅H₁₃NO₃S₂
• Molecular weight: 319.39 g/mol
• CAS number: 82159-09-9
• InChIKey: CHNUOJQWGUIOLD-NFZZJPOKSA-N
• PubChem CID: 1549120

C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Epalrestat used for?

DrugCentral lists the following indications for Epalrestat: Diabetic neuropathy.

How does Epalrestat work?

Its molecular targets in DrugCentral include Akr1b1, GSK3B, AKR1B1 (inhibitor) and AKR1B1.

When was Epalrestat first approved?

Epalrestat was first approved by the YEAR INTRODUCED in 1992.

What is the chemical formula of Epalrestat?

Epalrestat has the molecular formula C15H13NO3S2 and a molecular weight of 319.39 g/mol.

Sources

• DrugCentral drug card 1021 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL56337 — compound record and bioactivity
• PubChem CID 1549120 — chemical identifiers
• DrugBank DB15293 — drug record
• FDA UNII 424DV0807X — substance identity
• UniProt P49841 (GSK3B) — target protein
• UniProt P15121 (AKR1B1) — target protein
• UniProt O60218 (AKR1B10) — target protein
• UniProt Q02928 (CYP4A11) — target protein
• UniProt P14550 (AKR1A1) — target protein
• UniProt Q00796 (SORD) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.